484 related articles for article (PubMed ID: 23611368)
41. Ticagrelor Inhibits Toll-Like and Protease-Activated Receptor Mediated Platelet Activation in Acute Coronary Syndromes.
Wadowski PP; Weikert C; Pultar J; Lee S; Eichelberger B; Koppensteiner R; Lang IM; Panzer S; Gremmel T
Cardiovasc Drugs Ther; 2020 Feb; 34(1):53-63. PubMed ID: 32062795
[TBL] [Abstract][Full Text] [Related]
42. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
Wallentin L; Varenhorst C; James S; Erlinge D; Braun OO; Jakubowski JA; Sugidachi A; Winters KJ; Siegbahn A
Eur Heart J; 2008 Jan; 29(1):21-30. PubMed ID: 18055486
[TBL] [Abstract][Full Text] [Related]
43. Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting.
Pankert M; Quilici J; Loundou AD; Verdier V; Lambert M; Deharo P; Bonnet G; Gaborit B; Morange PE; Valéro R; Dutour A; Bonnet JL; Alessi MC; Cuisset T
Am J Cardiol; 2014 Jan; 113(1):54-9. PubMed ID: 24182762
[TBL] [Abstract][Full Text] [Related]
44. Residual platelet reactivity in low-dose aspirin-treated patients with class 1 obesity.
Lee S; Eichelberger B; Kopp CW; Panzer S; Gremmel T
Vascul Pharmacol; 2021 Feb; 136():106819. PubMed ID: 33207279
[TBL] [Abstract][Full Text] [Related]
45. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
[TBL] [Abstract][Full Text] [Related]
46. Decreased platelet inhibition by P2Y12 receptor blockers in anaemia.
Wadowski PP; Kopp CW; Koppensteiner R; Lang IM; Pultar J; Lee S; Weikert C; Panzer S; Gremmel T
Eur J Clin Invest; 2018 Jan; 48(1):. PubMed ID: 29171876
[TBL] [Abstract][Full Text] [Related]
47. Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI.
Behr T; Kuch B; Behr W; von Scheidt W
Clin Res Cardiol; 2011 Oct; 100(10):907-14. PubMed ID: 21533581
[TBL] [Abstract][Full Text] [Related]
48. The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
J Cardiovasc Pharmacol; 2010 Nov; 56(5):532-9. PubMed ID: 20729752
[TBL] [Abstract][Full Text] [Related]
49. Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease.
Perneby C; Wallén NH; Hofman-Bang C; Tornvall P; Ivert T; Li N; Hjemdahl P
Thromb Haemost; 2007 Dec; 98(6):1316-22. PubMed ID: 18064330
[TBL] [Abstract][Full Text] [Related]
50. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Heart; 2010 Feb; 96(3):186-9. PubMed ID: 19687016
[TBL] [Abstract][Full Text] [Related]
51. Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions.
Hosokawa K; Ohnishi T; Sameshima H; Miura N; Ito T; Koide T; Maruyama I
Thromb Haemost; 2013 Jan; 109(1):102-11. PubMed ID: 23179055
[TBL] [Abstract][Full Text] [Related]
52. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
Freynhofer MK; Brozovic I; Bruno V; Farhan S; Vogel B; Jakl G; Willheim M; Hübl W; Wojta J; Huber K
Thromb Haemost; 2011 Aug; 106(2):230-9. PubMed ID: 21614416
[TBL] [Abstract][Full Text] [Related]
53. Platelet activation and inhibition in sickle cell disease (pains) study.
Frelinger AL; Jakubowski JA; Brooks JK; Carmichael SL; Berny-Lang MA; Barnard MR; Heeney MM; Michelson AD
Platelets; 2014; 25(1):27-35. PubMed ID: 23469943
[TBL] [Abstract][Full Text] [Related]
54. In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization.
Gremmel T; Michelson AD; Frelinger AL
Platelets; 2016 Jun; 27(4):308-16. PubMed ID: 26556638
[TBL] [Abstract][Full Text] [Related]
55. Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis.
Gurbel PA; Samara WM; Bliden KP
Platelets; 2004 Mar; 15(2):95-9. PubMed ID: 15154601
[TBL] [Abstract][Full Text] [Related]
56. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Gurbel PA; Bliden KP; Hiatt BL; O'Connor CM
Circulation; 2003 Jun; 107(23):2908-13. PubMed ID: 12796140
[TBL] [Abstract][Full Text] [Related]
57. Postmenopausal women have an increased maximal platelet reactivity compared to men despite dual antiplatelet therapy.
Bobbert P; Stellbaum C; Steffens D; Schütte C; Bobbert T; Schultheiss HP; Rauch U
Blood Coagul Fibrinolysis; 2012 Dec; 23(8):723-8. PubMed ID: 23135379
[TBL] [Abstract][Full Text] [Related]
58. Platelet activation biomarkers in Berkeley sickle cell mice and the response to prasugrel.
Ohno K; Tanaka H; Samata N; Jakubowski JA; Tomizawa A; Mizuno M; Sugidachi A
Thromb Res; 2014 Oct; 134(4):889-94. PubMed ID: 25130912
[TBL] [Abstract][Full Text] [Related]
59. A high maintenance dose increases the inhibitory response to clopidogrel in patients with high on-treatment residual platelet reactivity.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Int J Cardiol; 2012 Oct; 160(2):109-13. PubMed ID: 21546102
[TBL] [Abstract][Full Text] [Related]
60. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
